Did you know?

Bristol Myers Squibb Co. analyst ratings, historical stock prices, earnings estimates & actuals. BMY updated stock price target summary.Bristol-Myers Squibb Co’s stock is NA in 2023, NA in the previous five trading days and down 37.41% in the past year. Currently, Bristol-Myers Squibb Co’s price-earnings ratio is 12.5. Bristol-Myers Squibb Co’s trailing 12-month revenue is $44.9 billion with a 18.4% net profit margin. Year-over-year quarterly sales growth most recently ...In the last 3 months, 4 analysts have offered 12-month price targets for Bristol-Myers Squibb. The company has an average price target of $76.5 with a high of $85.00 and a low of $65.00. Below is ...If we look at stock returns, Eli Lilly, with 15% returns in the last twelve months, has fared better than BMS, down 5%, and the broader S&P 500 index, down 11%.

The company reported net earnings attributable to Bristol Myers Squibb of $2.3 billion, or GAAP EPS of $1.07, in the first quarter, compared to $1.3 billion, or $0.59 per share, for the same period a year ago. In addition to the items discussed above, the higher GAAP EPS in the first quarter of 2023 was due to lower equity investments losses ...Bristol-Myers Squibb is expected to release its financial report for the fourth quarter of 2023 on Feb. 2. According to Seeking Alpha, revenue for the quarter is …Bristol Myers Squibb Co. engages in the discovery, development, licensing, manufacture, marketing, distribution, and sale of biopharmaceutical products.Reconciliations of these non-GAAP financial measures to the most comparable GAAP measures for a particular quarterly period are available on the company’s website at www.bms.com . Discover the stock split history of Bristol Myers Squibb and other stock-related corporate actions taken in the past.

1-800-721-5072. (toll free U.S. only) Report side effects or product quality complaints about legacy celgene products (ABRAXANE ® , IDHIFA ® , INREBIC ®, ISTODAX ®, POMALYST ®, REBLOZYL ®, REVLIMID ®, THALOMID ®, VIDAZA ®) Learn more >. Below is a list of our company's marketed products. Any linked documents and websites are intended ...Going by our Bristol Myers Squibb Valuation of $79 per share, based on $7.52 expected adjusted EPS and around 10x P/E multiple for 2021, there is an upside potential of 45% from its current levels ...The Bristol Myers Squibb 52-week high stock price is 81.42, which is 62.5% above the current share price. The Bristol Myers Squibb 52-week low stock price is 48.25, which is 3.7% below the current share price. The average Bristol Myers Squibb stock price for the last 52 weeks is 64.65. For more information on how our historical price data is ... ….

Reader Q&A - also see RECOMMENDED ARTICLES & FAQs. Bristol meyers squibb stock. Possible cause: Not clear bristol meyers squibb stock.

Get the latest Bristol-Myers Squibb Company (BMY) stock price, news, buy or sell recommendation, and investing advice from Wall Street professionals.Bristol-Myers Squibb Co. () Stock Market info Recommendations: Buy or sell Bristol-Myers Squibb stock? Wall Street Stock Market & Finance report, prediction for the future: You'll find the Bristol-Myers Squibb share forecasts, stock quote and buy / sell signals below.According to present data Bristol-Myers Squibb's BMY shares and potentially its …Find the latest historical data for Bristol-Myers Squibb Company Common Stock (BMY) at Nasdaq.com.

The Wall Street Analyst consensus on Bristol Myers Squibb ( NYSE: BMY) is overwhelmingly bullish. Out of 21 analyst ratings, nearly half (10) are very bullish, 4 are bullish, 7 are neutral, and 0 ...BRISTOL-MYERS SQUIBB CO. BRISTOL-MYERS SQUIBB CO 0R1F Overview - Search stock, chart, recent trades, company information, trading information, company news, fundamentals.

fmna stock Going by our Bristol Myers Squibb Valuation of $79 per share, based on $7.52 expected adjusted EPS and around 10x P/E multiple for 2021, there is an upside potential of 45% from its current levels ...Bristol-Myers Squibb Co’s stock is NA in 2023, NA in the previous five trading days and down 37.41% in the past year. Currently, Bristol-Myers Squibb Co’s price-earnings ratio is 12.5. Bristol-Myers Squibb Co’s trailing 12-month revenue is $44.9 billion with a 18.4% net profit margin. Year-over-year quarterly sales growth most recently ... alamos gold stockcigna preferred network access dental plan PRINCETON, N.J.--(BUSINESS WIRE)-- Bristol Myers Squibb (NYSE:BMY) today reports results for the second quarter of 2023, which reflect continued execution against our strategic priorities. “This was an important quarter for Bristol Myers Squibb,” said Giovanni Caforio, M.D., board chair and chief executive officer, Bristol Myers …Many Bristol-Myers Squibb Company insiders ditched their stock over the past year, which may be of interest to the company's shareholders.When evaluating insider transactions, knowing whether ... liberty 1964 half dollar value When I last provided analysis of Bristol-Myers Squibb Company (NYSE:BMY) - the New York-based Pharma giant that is the 6th-largest Pharmaceutical in the U.S. by market capitalization - at the end ...View our detailed stock quote, explore our stock chart and look up our historical stock quote. Quotes delayed at least 20 minutes. Market data provided by Ticker Tech. insurance stockshow to get a broker for metatrader 4zero spread forex broker Nov 30, 2023 · The Last 12 Months Of Insider Transactions At Bristol-Myers Squibb. The Executive Chairman of the Board, Giovanni Caforio, made the biggest insider sale in the last 12 months. That single ... 26 окт. 2023 г. ... Shares of Bristol Myers Squibb (BMY) fell Thursday after the company reported that sales of the drug maker's popular Revlimid blood cancer ... daily stock trades Nov 29, 2023 · Bristol Myers Squibb (NYSE: BMY) reported its Q3 results last month, with revenues meeting and earnings beating the street estimates, and we believe that BMY stock is 21 days ago - Forbes Bristol Myers Squibb to Participate in the 2023 Jefferies London Healthcare Conference Bristol-Myers Squibb has a consensus target price of $63.59, indicating a potential upside of 26.92%. Given Bristol-Myers Squibb's stronger consensus rating and higher probable upside, research analysts plainly believe Pfizer is more favorable than Bristol-Myers Squibb. amt stock dividendrun stock forecasttruist stock dividend Bristol-Myers Squibb (BMY) Valuation: Is BMY Stock Expensive Or Cheap? 2021-07-14 . Financials.